Piper Jaffray Companies assumed coverage on shares of Ovid Therapeutics (NASDAQ:OVID) in a research note issued to investors on Friday morning, MarketBeat reports. The firm issued an overweight rating and a $20.00 price target on the stock.
OVID has been the topic of several other research reports. Zacks Investment Research upgraded Ovid Therapeutics from a hold rating to a buy rating and set a $11.00 target price on the stock in a report on Friday, January 12th. ValuEngine upgraded Ovid Therapeutics from a sell rating to a hold rating in a report on Friday, February 2nd. One analyst has rated the stock with a sell rating and six have given a buy rating to the stock. The stock has a consensus rating of Buy and a consensus target price of $19.50.
Shares of Ovid Therapeutics (NASDAQ OVID) opened at $8.49 on Friday. Ovid Therapeutics has a 1-year low of $5.28 and a 1-year high of $15.93.
COPYRIGHT VIOLATION WARNING: This story was originally posted by Markets Daily and is owned by of Markets Daily. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://www.themarketsdaily.com/2018/03/12/ovid-therapeutics-ovid-coverage-initiated-at-piper-jaffray-companies.html.
Ovid Therapeutics Company Profile
Ovid Therapeutics Inc (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist.
Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.